SFDA Suspends European Pharmaceutical Factory Due to Critical Manufacturing Violations

The Saudi Food and Drug Authority (SFDA) has announced the suspension of a European pharmaceutical factory's registration, following an inspection, part of the SFDA's external monitoring program, which uncovered critical and fundamental violations of Good Manufacturing Practices (GMP).

 According to an SFDA press release issued today, the detected violations specifically concerned the factory's manufacturing procedures and its internal quality system. These shortcomings posed a direct threat to the safety of pharmaceutical products destined for export.

 As a result of a thorough technical assessment, the SFDA promptly implemented the suspension as a precautionary measure to prevent the distribution of any potentially risky products to consumers.

 This move, added the release, aligns with the SFDA's proactive strategy of inspecting foreign supplier factories. These on-site evaluations are conducted in accordance with international regulatory standards, meticulously reviewing manufacturing and quality systems, operational records, and storage and distribution practices to ensure adherence to approved regulatory requirements.

 Several European regulatory authorities have contacted the SFDA to review the technical observations made at the factory and to take necessary actions, highlighting the increasing confidence in the authority's expertise, the reliability of its regulatory findings, and its impactful role within the global framework for drug safety.

 The SFDA reiterated that monitoring foreign factories is a cornerstone of its regulatory framework. This oversight is conducted with complete independence, relying on scientific and field evidence. The authority emphasized that consumer protection remains its utmost priority, and it will not hesitate to take decisive action whenever a defect that could compromise the safety of pharmaceutical products is identified.